Xenografts Evolve Differently than Tumors.
In a study of 1,110 patient-derived xenografts (PDX) from 24 cancer types, researchers found that the genomic landscape of these tools changes dramatically over time. Some of the genetic changes observed have been associated with drug sensitivity in previous studies, raising questions about the use of PDXs to predict drug response in personalized medicine.